Identification of a chemotherapy resistance factor in breast cancer patients

Chemotherapy is a key part of the standard treatment regimen for triple-negative breast cancer patients whose cancer lacks expression of estrogen and progesterone receptors and the human epidermal growth factor receptor 2 (HER2). While many patients respond well to chemotherapy, a significant fraction of those treated are resistant to chemotherapy or will develop recurrent tumors that are chemoresistant.

In this issue of JCI Insight, a research team led by Mercedes Rincon at the University of Vermont identified low expression of methylation-controlled J protein (MCJ) as a marker of poor response to chemotherapy.

In a prospectives study of 62 breast cancer patients, they demonstrated that MCJ expression correlates with pathological and clinical responses to neoadjuvant chemotherapy.

Further, by analyzing a large clinical data set from breast cancer repositories, they found that with low-MCJ-expressing tumors had reduced relapse-free survival. Lastly, they examined a mammary tumor mouse model and showed that mice deficient in MCJ had larger tumors and increased chemoresistance.

Their study suggests that MCJ may be useful as a marker of response and could be a potential therapeutic target for breast cancer treatment.

More information: Maria J. Fernández-Cabezudo et al, Deficiency of mitochondrial modulator MCJ promotes chemoresistance in breast cancer, JCI Insight (2016). DOI: 10.1172/jci.insight.86873

Provided by JCI Journals
Citation: Identification of a chemotherapy resistance factor in breast cancer patients (2016, May 19) retrieved 29 November 2023 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Multiplexed immunofluorescence reveals protein expression alterations in breast cancer


Feedback to editors